🟢 Capricor Therapeutics is trading 6.1% up today after amended Deramiocel BLA strategy and Cantor upgrade

Capricor Therapeutics is trading 6.09% up now at $7.05, extending the August 14 rally after management outlined an amended Deramiocel BLA strategy focused on skeletal-muscle function.

• The FDA remains actively reviewing the application, with an August 22 PDUFA date.
• Cantor Fitzgerald upgraded the shares to Overweight and raised its target to $28.00.
• Mixed earnings included a $40.7 million quarterly loss and no revenue.